Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TP-10 (AVANT Immunotherapeutics).

P Rioux1

  • 1PMB 214, Lexington, MA 02421-7934, USA. prioux@ieee.org

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clues about the functional neuroanatomy of verbal working memory: a study of resting brain glucose metabolism in Parkinson's disease.

European journal of neurology·2013
Same author

Childhood cognitive ability accounts for associations between cognitive ability and brain cortical thickness in old age.

Molecular psychiatry·2013
Same author

Suicide attempts and job insecurity: a complex association.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

CAMPATH-1H (Cambridge University).

IDrugs : the investigational drugs journal·2005
Same author

Premorbid IQ estimates from a multiple aptitude test battery: regression vs. equating.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2003
Same author

Use of brook char (Salvelinus fontinalis) physiological responses to stress as a teaching exercise.

Advances in physiology education·2000
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

TP-10, a soluble complement receptor type 1 (sCR1), is being developed to treat reperfusion injury and organ rejection. Clinical trials in adults and infants undergoing cardiac surgery are evaluating its safety and efficacy in mitigating organ damage.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Recombinant soluble complement receptor type 1 (sCR1), known as TP-10, is under development by AVANT Immunotherapeutics.
  • TP-10 targets complement-mediated conditions, including reperfusion injury, organ rejection, and autoimmune diseases.

Purpose of the Study:

  • To evaluate the safety and efficacy of TP-10 in preventing and reducing organ injury.
  • To assess TP-10's potential in mitigating damage during cardiopulmonary bypass in cardiac surgery patients.
  • To explore TP-10's utility in treating conditions like adult respiratory distress syndrome (ARDS) and in organ transplantation.

Main Methods:

  • Phase II placebo-controlled trials involving adult and infant patients undergoing cardiac surgery with cardiopulmonary bypass.
  • Phase I/II trials in infants undergoing cardiac surgery for congenital heart defects.

Related Experiment Videos

  • Phase I safety trials in adult patients at risk for ARDS and myocardial infarction, and in pediatric cardiac surgery patients.

    • Main Results:

    • TP-10 demonstrated favorable results in animal models of reperfusion injury and xenograft rejection.
    • Phase I trials indicated that TP-10 is well tolerated in adult and pediatric patient populations.
    • Development for ARDS was ceased following a Phase IIa trial, but TP-10 was licensed for transplantation.

    Conclusions:

    • TP-10 shows potential for treating a range of complement-mediated conditions.
    • Ongoing clinical trials aim to establish TP-10's efficacy in cardiac surgery patients.
    • Further development is planned, including pivotal Phase III trials, based on trial outcomes.